Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 6/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793430 | 0.90 | HPGDS (0.83) | HPGDSHPGDHTTNPC1RAB9A | |
| SCHEMBL7485708 | 0.82 | HPGDS (0.71) | HPGDSHPGDHTTNPC1RAB9A | |
| SCHEMBL8439895 | 0.82 | HPGDS (0.78) | HPGDSHPGDHTTNPC1RAB9A | |
| SCHEMBL158020 | 0.82 | HPGDS (1.00) | HPGDSHPGDHTTNPC1RAB9A | |
| SCHEMBL5591866 | 0.81 | HPGDS (0.69) | HPGDSHPGDHTTNPC1RAB9A | |
| SCHEMBL11306574 | 0.81 | HPGDS (0.69) | HPGDSHPGDHTTNPC1RAB9A | |
| SCHEMBL2074541 | 0.81 | HPGDS (0.69) | HPGDSHPGDHTTNPC1RAB9A | |
| SCHEMBL6326690 | 0.81 | HPGD (1.00) | HPGDSHPGDHTTNPC1RAB9A | |
| SCHEMBL2760408 | 0.81 | HPGDS (0.69) | HPGDSHPGDHTTNPC1RAB9A | |
| SCHEMBL7075260 | 0.81 | HPGDS (0.69) | HPGDSHPGDHTTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325916-A1 | 5-ARYL INDAN-1-ONE AND ANALOGS USEFUL AS PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| US-20080119537-A1 | 5-Aryl indan-1 one and analogs useful as progesterone receptor modulators | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| US-7319152-B2 | Contraception, hormone replacement therapy, cycle-related symptoms, or benign or malignant neoplastic disease; -methyl-5-(5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)-1H-pyrrole-2-carbonitrile | WYETH (US) | 2008-01-15 | — | — | US | disclosed |
| US-20070066628-A1 | 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066675-A1 | 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2004046141-A1 | NEW TRICYCLIC ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2004-06-03 | — | — | WO | disclosed |
| EP-0339599-B1 | Process for producing acylaromatic compounds | SUMITOMO CHEMICAL CO (JP) | 1996-08-21 | — | — | EP | disclosed |
| EP-0339599-A2 | Process for producing acylaromatic compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1989-11-02 | — | — | EP | disclosed |
| US-4235896-A | Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same | ORCHIMED S.A. (CH) | 1980-11-25 | — | — | US | disclosed |
| US-4179515-A | HYPOLIPEMIC, HYPOCHOLESTEROLEMIC, CHOLAGOGIC | ORCHIMED S. A. (CH) | 1979-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066628-A1 | 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators | PGR, CYP19A1, GNRHR | HPGDS 319/4885HPGD 201/4885HTT 4291/4885 |
| US-20070066675-A1 | 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators | PGR, CYP19A1, GNRHR | HPGDS 629/4885HPGD 434/4885HTT 4005/4885 |
| US-20090325916-A1 | 5-ARYL INDAN-1-ONE AND ANALOGS USEFUL AS PROGESTERONE RECEPTOR MODULATORS | CYP19A1, PGR, NR5A1 | HPGDS 189/4885HPGD 108/4885HTT 4428/4885 |
| US-20080119537-A1 | 5-Aryl indan-1 one and analogs useful as progesterone receptor modulators | CYP19A1, PGR, NR5A1 | HPGDS 185/4885HPGD 103/4885HTT 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.